Hostname: page-component-76fb5796d-9pm4c Total loading time: 0 Render date: 2024-04-26T10:04:58.523Z Has data issue: false hasContentIssue false
  • English
  • Français

Clinical Efficacy of Valproic Acid in Relation to Plasma Levels

Published online by Cambridge University Press:  18 September 2015

J. Bruni ,
B.J. Wilder ,
L.J. Willmore ,
H.J. Villarreal ,
M. Thomas  and
L.E.M. Crawford
J. Bruni
Affiliation:
Neurology Service, Veterans Administration Hospital; Department of Neurology, University of Florida College of Medicine, Gainesville, Florida
B.J. Wilder*
Affiliation:
Neurology Service, Veterans Administration Hospital; Department of Neurology, University of Florida College of Medicine, Gainesville, Florida
L.J. Willmore
Affiliation:
Neurology Service, Veterans Administration Hospital; Department of Neurology, University of Florida College of Medicine, Gainesville, Florida
H.J. Villarreal
Affiliation:
Neurology Service, Veterans Administration Hospital; Department of Neurology, University of Florida College of Medicine, Gainesville, Florida
M. Thomas
Affiliation:
Neurology Service, Veterans Administration Hospital; Department of Neurology, University of Florida College of Medicine, Gainesville, Florida
L.E.M. Crawford
Affiliation:
Neurology Service, Veterans Administration Hospital; Department of Neurology, University of Florida College of Medicine, Gainesville, Florida
*
Neurology Service (127), Veterans Administration Hospital, Gainesville, Florida 32602 U.S.A.
Rights & Permissions [Opens in a new window]

Summary:

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Valproic acid is a new antiepileptic drug recently introduced in the United States for the treatment of absence seizures. In this study on patients with absence and other seizure types, the majority of patients achieved optimal control within four weeks of therapy. No patient responded to valproic acid who did not show an initial clinical response by four weeks of active therapy. Optimal response was generally achieved when plasma levels were greater than 55 μg/ml. Excellent clinical response was observed in the treatment of absence and myoclonic seizures. Twenty-two patients continued in a long term study have maintained the same degree of seizure control as observed at the time of optimal control.

Type
Research Article
Information
Canadian Journal of Neurological Sciences , Volume 5 , Issue 4 , November 1978 , pp. 385 - 387
Copyright
Copyright © Canadian Neurological Sciences Federation 1978

References

REFERENCES

Adams, D.J., Luders, H., and Pippenger, C. (1978). Sodium valproate in the treatment of intractable seizure disorders: A clinical and electroencephalographic study. Neurology 28: 152–157.CrossRefGoogle ScholarPubMed
Bruni, J., Wilder, B.J., Willmore, L.J., Perchalski, R.J. and Villar-Real, H.J. (1978). Kinetics of steady state valproic acid in epileptic patients. Clin. Pharmacol. Ther. (Submitted).CrossRefGoogle Scholar
Buchtal, F. and Lennox-Buchtal, M.A. (1972). Diphenylhydantoin: Relation of anticonvulsant effect to concentration in serum. In: Antiepileptic Drugs, Woodbury, D.M., Penry, J.K. and Schmidt, R.P., Eds., New York: Raven Press, pp 193–209.Google Scholar
Buchtal, F. and Lennox-Buchtal, M.A. (1972). Phénobarbital: Relation of serum concentration to control of seizures. In: Antiepileptic Drugs, Woodbury, D.M., Penry, J.K. and Schmidt, R.P., Eds., New York: Raven Press, pp 335–343.Google Scholar
Kutt, H. and Penry, J.K. (1974). Usefulness of blood levels of antiepileptic drugs. Arch. Neurol. 31: 283–288.CrossRefGoogle ScholarPubMed
Loiseau, P., Brachet, A. and Henry, P. (1975). Concentration of dipropylacetate in plasma. Epilepsia 16: 609–615.CrossRefGoogle ScholarPubMed
Mattson, R.H., Cramer, J.A., Williamson, P.D. and Novelly, R.A. (1978). Valproic acid in epilepsy: Clinical and pharmacological effects. Ann. Neurol. 3: 20–25.CrossRefGoogle ScholarPubMed
Meijer, J.W.A. and Hessing-Brand, L. (1973). Determination of lower fatty acids, particularly the antiepileptic dipropylacetic acid, in biological material by means of micro-diffusion and gas chromatography. Clin. Chem. Acta 43: 215–222.CrossRefGoogle ScholarPubMed
Penry, J.K., Porter, R.J., and Drelfuss, F.E. (1972). Ethosuximide: Relation of plasma levels to clinical control. In: Antiepileptic Drugs, Woodbury, D M., Penry, J.K., and Schmidt, R.P., Eds., New York: Raven Press, pp 431–441.Google Scholar
Perchalski, R.J.Scott, K.N., Wilder, B.J., and Hammer, R.H. (1973). Rapid simultaneous GLC determination of phénobarbital, primidone and diphenylhydantoin. J. Pharm. Sci. 62: 1735–1736.CrossRefGoogle ScholarPubMed
Schobben, F. and Van Der Kleun, E. (1974). Determination of Sodium di-n-propylacetate in plasma by gas-liquid chromatography. Pharm. Week. 109: 30–33.Google Scholar
Schobben, F., Van Der Kleun, E. and Gabreels, F.J.M. (1975). Pharmacokinetics of di-n-propylacetate in epileptic patients. Europ. J. Clin. Pharmacol. 8: 97–105.Google Scholar
Sherwin, A.L., and Robb, J.P. (1972). Ethosuximide: Relation of plasma levels to clinical control. In: Antiepileptic Drugs. Woodbury, D.M., Penry, T.K. and Schmidt, R.P., Eds., New York: Raven Press, pp 443–448.Google Scholar
Simon, D., Penry, J.K. (1975). Sodium di-n-propylacetate (DPA) in The Treatment of epilepsy. A review. Epilepsia 16: 549–573.CrossRefGoogle ScholarPubMed
Villarreal, H.J., Wilder, B.J., Bauman, A.W., Hammond, E.J., Willmore, L.J. and Bruni, J. (1978). Effect of valproic acid on spike and wave discharge in patients with absence seizures. Neurology (In Press).CrossRefGoogle ScholarPubMed
Wilder, B.J., Willmore, L.J., Bruni, J. and Villarreal, H.J. (1978). Valproic acid: Interaction with other anticonvulsant drugs. Neurology (In Press).CrossRefGoogle ScholarPubMed
Willmore, L.J., Wilder, B.J., Bruni, J. and Villarreal, H.J. (1978). Effects of Valproic acid on hepatic function. Neurology. (Submitted).CrossRefGoogle ScholarPubMed